Great development that Roche have validated the Phylomers intra-cellular activity & now identified the potential of several of those to also cross the blood-brain barrier - an area very few in the industry have been able to access. Success there will have far reaching benefits.
My guess to the direct targets that Roche are focussing on through the Phylomers are Alzheimers &/or Parkinsons Disease areas where Roche are currently active & both have a very large unmet need.
Roche partnership is still very frustrating though in my opinion as it remains largely sealed under confidentiality agreements & different structure to the more recent partnerships Pfizer/AZ with potential from the agreement stitched up. I was kind of under the impression from previous releases that moving to second stage was going to see the company re-structure the deal & maybe release a little further informaion as opposed to guessing specific disease targets.
No release as of it yet but once it enters the clinic & moves to Phase 1 (should it happen), deal terms will then be made public & the collaboration will be publicly released by Roche under its own banner.
PYC Price at posting:
6.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)